Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ardelyx Inc (NQ: ARDX )

6.090 +0.220 (+3.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx Inc

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
From Ardelyx, Inc.
Via GlobeNewswire
The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter
Explore why these stocks may explode and could be game-changers in biotechnology, hotels, resorts, cruise lines, and application software. 
Via InvestorPlace
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Where Ardelyx Stands With Analysts
Via Benzinga
Recap: Ardelyx Q4 Earnings
Via Benzinga
How Is The Market Feeling About Ardelyx?
Via Benzinga
Wedbush Maintains Outperform Rating for Ardelyx: Here's What You Need To Know
Via Benzinga
The Millionaire’s Watchlist: 3 Stocks Set for a Meteoric Rise
From biotechnology to digital tech endeavors, these stocks offer huge promise for the future, making them stocks to buy now. 
Via InvestorPlace
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Via AB Newswire
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
Stocks on the Launchpad: The Next 3 Market Sensations
Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments 
Via InvestorPlace
What's Going On With Ardelyx Stock After Earnings?
Ardelyx reported ending 2023 with $184.3 million in cash and investments and expects full-year 2024 U.S. net product sales revenue for Ibsrela to be between $140 million and $150 million. Wedbush... 
Via Benzinga
Why AXT Shares Are Trading Higher By Around 36%; Here Are 20 Stocks Moving Premarket
Shares of AXT, Inc. (NASDAQ: AXTI) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Ardelyx Posts Q4 Loss, Joins MercadoLibre, Booking Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 25 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Ardelyx Reports Mixed Q4 Results: Earnings Miss, Revenue Beat
Ardelyx reported quarterly losses of 12 cents per share which missed the analyst consensus estimate of losses of 10 cents by 20%. The company reported quarterly sales of $34.36 million, beating the... 
Via Benzinga
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
Pounce on the electric surge of analyst upgrades, guiding you through market uncertainties with considerable aplomb. 
Via InvestorPlace
3 Revolutionary Biotech Stocks Poised for 10X Surge
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
Via InvestorPlace
3 Unstoppable Russell 2000 to Buy in February
These are a few companies that are within the Russell 2000 Index that offer investors great returns and a bright future. 
Via InvestorPlace
3 Sleeper Stocks Under $15 Ready to Explode by 2029
Discover 3 under-$15 stocks primed for a 2029 explosion, from fintech disruptors to biotech pioneers tackling untreatable rare diseases. 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
7 Small-Cap Stocks to Buy for Big Gains in 2024
Small-cap stocks are a great way to diversify your portfolio and set yourself up for some potentially dynamic gains. 
Via InvestorPlace
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
The 3 Best Under-$10 Stocks to Buy in January 2024
These are a few companies for investors looking for inexpensive options that still offer great earnings potential. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.